SAB Biotherapeutics Ownership | Who Owns SAB Biotherapeutics?

SAB Biotherapeutics Ownership Summary

SAB Biotherapeutics is owned by 169.79% institutional investors, 12.36% insiders. Vivo capital is the largest institutional shareholder, holding 122.87% of SABS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.45% of its assets in SAB Biotherapeutics shares.

SABS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	SAB Biotherapeutics	169.79%	12.36%	-82.15%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vivo capital	11.42M	122.87%	$22.95M
Commodore capital lp	4.40M	47.36%	$8.85M
Ra capital management	4.40M	47.36%	$8.85M
Woodline partners lp	2.85M	30.67%	$5.73M
Sessa capital im	2.20M	23.65%	$4.42M
Vanguard group	1.85M	17.33%	$6.91M
Bvf inc/il	932.70K	10.04%	$1.87M
Propel bio management	652.88K	6.12%	$2.44M
Sphera funds management	566.39K	6.09%	$1.14M
Jefferies financial group	580.33K	5.44%	$2.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Propel bio management	652.88K	2.08%	$2.44M
Vivo capital	11.42M	1.85%	$22.95M
Caxton	10.53K	0.92%	$39.37K
Commodore capital lp	4.40M	0.43%	$8.85M
Sphera funds management	566.39K	0.24%	$1.14M
Ra capital management	4.40M	0.11%	$8.85M
Sessa capital im	2.20M	0.10%	$4.42M
Bvf inc/il	932.70K	0.08%	$1.87M
Awm investment company	200.00K	0.07%	$748.00K
Woodline partners lp	2.85M	0.03%	$5.73M

Top Buyers

Holder	Shares	% Assets	Change
Vivo capital	11.42M	1.85%	11.42M
Commodore capital lp	4.40M	0.43%	4.40M
Ra capital management	4.40M	0.11%	4.40M
Woodline partners lp	2.85M	0.03%	2.85M
Sessa capital im	2.20M	0.10%	1.74M

Top Sellers

Holder	Shares	% Assets	Change
Renaissance	-	-	-80.84K
Silver oak securities	-	-	-20.19K
Xtx topco	-	-	-16.55K
Dimensional fund advisors lp	-	-	-15.78K
Creative planning	-	-	-11.85K

New Positions

Holder	Shares	% Assets	Change	Value
Vivo capital	11.42M	1.85%	11.42M	$22.95M
Commodore capital lp	4.40M	0.43%	4.40M	$8.85M
Ra capital management	4.40M	0.11%	4.40M	$8.85M
Woodline partners lp	2.85M	0.03%	2.85M	$5.73M
Propel bio management	652.88K	2.08%	652.88K	$2.44M

Sold Out

Holder	Change
Raymond james financial	-45.00
Sachetta	-4.10K
Creative planning	-11.85K
Dimensional fund advisors lp	-15.78K
Xtx topco	-16.55K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	30	-11.76%	18,100,153	-35.41%	169	0.19%	18	-18.18%	4	100.00%
Sep 30, 2025	34	36.00%	28,023,938	1356.64%	301	70.37%	22	144.44%	2	-50.00%
Jun 30, 2025	25	-3.85%	1,923,784	-12.93%	20	3.66%	9	-18.18%	4	-33.33%
Mar 31, 2025	26	4.00%	2,209,552	-15.93%	23	2.95%	11	22.22%	6	-14.29%
Dec 31, 2024	25	4.17%	2,628,252	-16.34%	28	2.46%	9	28.57%	7	75.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.64M	3.45%	-
Simplify Propel Opportunities ETF	208.23K	0.44%	-
Vanguard Institutional Extnd Mkt Idx Tr	76.49K	0.16%	-
A4Investments SICAV SIF ACCI IlanaA2EURH	75.00K	0.16%	-
Fidelity Extended Market Index	47.67K	0.10%	5.27K
Spartan Extended Market Index Pool E	8.36K	0.09%	356.00
Fidelity Nasdaq Composite Index	32.16K	0.07%	27.23K
Vanguard Instl Ttl Stck Mkt Idx Tr	31.85K	0.07%	-
Vanguard Instl Ttl Stk Mkt Idx InstlPls	27.86K	0.06%	-
Vanguard Balanced Index Inv	26.11K	0.05%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 07, 2023	Sullivan Eddie Joe	Chief Executive Officer	Buy	$1.53K
Nov 30, 2023	King Michael	CHIEF FINANCIAL OFFICER	Buy	$4.50K
Nov 29, 2023	Reich Samuel J	Executive Chairman	Buy	$9.84K
Sep 13, 2022	HAMILTON CHRISTINE E		Buy	$7.30K
Sep 07, 2022	Sullivan Eddie Joe	CHIEF EXECUTIVE OFFICER	Buy	$10.32K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-
2025 Q1	-	-
2024 Q4	-	-

SABS Ownership FAQ

Who Owns SAB Biotherapeutics?

SAB Biotherapeutics shareholders are primarily institutional investors at 169.79%, followed by 12.36% insiders and -82.15% retail investors. The average institutional ownership in SAB Biotherapeutics's industry, Biotech Stocks , is 381.47%, which SAB Biotherapeutics falls below.

Who owns the most shares of SAB Biotherapeutics?

SAB Biotherapeutics’s largest shareholders are Vivo capital (11.42M shares, 122.87%), Commodore capital lp (4.4M shares, 47.36%), and Ra capital management (4.4M shares, 47.36%). Together, they hold 217.58% of SAB Biotherapeutics’s total shares outstanding.

Does Blackrock own SAB Biotherapeutics?

BlackRock is not among the top 10 institutional shareholders of SAB Biotherapeutics.

Who is SAB Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Propel bio management is SAB Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 2.08% of its assets in 652.88K SAB Biotherapeutics shares, valued at 2.44M$.

Who is the top mutual fund holder of SAB Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of SAB Biotherapeutics shares, with 3.45% of its total shares outstanding invested in 1.64M SAB Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools